达比加群酯在持续性心房颤动经导管射频消融患者围手术期抗凝治疗中的应用

摘要

目的 探讨达比加群酯在持续性心房颤动(房颤)接受导管射频消融术(RFCA)患者围手术期抗凝治疗中的安全性和有效性.方法 将131例行RFCA的持续性房颤患者随机分为达比加群酯组(A组,58例)和华法林组(B组,73例),比较两组临床结局.结果 两组患者术后均无死亡、大出血及血栓栓塞事件发生;A组缺血性脑病发生率与B组比较无统计学差异(3.45% vs.4.11%)(P>0.05);A组出血总发生率低于B组(3.45% vs.15.07%)(P<0.05).结论 达比加群酯可作为安全、稳定的持续性房颤患者RFCA围手术期的抗凝治疗药物.%Objective To investigate the safety and effectiveness of dabigatran in the perioperative anticoagulant therapy of patients with persistent atrial fibrillation undergoing radiofrequency catheter ablation(RFCA).Methods A total of 131 patients with persistent atrial fibrillation undergoing RFCA was randomly divided into two groups of A(treated with dabigatran,58 cases) and B(treated with warfarin,73 cases).The clinical outcomes were compared between two groups.Results No death,massive hemorrhage and thromboembolism events occurred in both groups after operation.There was no statistical difference in the incidence of ischemic encephalopathy between groups of A and B(3.45% vs.4.11%)(P>0.05).But the overall incidence of total hemorrhage in group A was less than that in group B(3.45% vs.15.07%)(P<0.05).Conclusion Dabigatran used perioperatively can be considered as a safe and effective anticoagulant drug in the patients with persistent atrial fibrillation undergoing RFCA.